Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) a clinical stage drug advancement firm targeting chronic, serious fibrotic and inflammatory diseases, reported positive topline data from its Phase 2 trial assessing Resunab for the cure of systemic sclerosis. JBT-101 exceled placebo in the ACR Combined Response Index in CRISS score, touching 33% at week 16, compared 0% for placebo.

The better the CRISS score the more the improvement. A CRISS score ≥ 20% can be stated a medically significant enhancement. The variance in CRISS scores between placebo groups and JBT-101 over the trial duration was considerable (p = 0.044). Differences in segmental levels of CRISS changes and responses from baseline in the 5 individual units of the CRISS score advanced clinical advantage of JBT-101.

The experts speak

Robert Spiera, M.D., the Principal Investigator in this study, stated that it is the first randomized, double-blind, placebo controlled study in diffuse CRISS to demonstrate a clinical advantage utilizing the CRISS as an endpoint, with a medication that was well-tolerated and safe in the study. This data bring hope to patients and also to their physicians that Resunab may be an effective medication for systemic sclerosis where presently there are no verified treatments.

Yuval Cohen, Ph.D., the Chief Executive Officer of Corbus Pharmaceuticals, said that the positive data of this trial surpass expectations and prove the unique process of action of Resunab. The medication drug previously showed consistent and clear evidence of activity in animal and cellular models, and also in healthy volunteers. It repeatedly showed that its arrangement with the CB2 receptor and its instigation of inflammatory resolution decodes into a powerful effect on fibrosis and inflammation.

With the information from this Phase 2 trial, the company now reveal that this action mechanism offered clinical advantages in subjects with systemic sclerosis in this study. The company look forward to the next phases in the advancement of this medication. Corbus CEO added that they are extremely grateful to the subjects, the clinical staff and their physicians, who participated in this study.

Previous articleUnited Cannabis Corp (OTCMKTS:CNAB) Files Application To Jamaica’s CRD
Next articleEagle Bulk Shipping Inc (NASDAQ:EGLE) Acquires SDARI-64 ‘Ultramax’ Newbuilding Vessel
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.